UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000028071
Receipt number R000030717
Scientific Title Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutaeted non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trial-
Date of disclosure of the study information 2017/07/04
Last modified on 2023/01/10 09:20:42

No. Disposal Last modified on Item of update
1 Insert 2017/07/04 18:25:49
2 Update 2018/01/05 14:33:33 Recruitment status
3 Update 2019/01/07 10:45:31 Public title
Public title
4 Update 2019/01/07 10:52:26 Narrative objectives1
Narrative objectives1
Primary outcomes
Primary outcomes
Key secondary outcomes
Key secondary outcomes
5 Update 2019/01/07 11:53:53 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
Target sample size
6 Update 2019/01/07 11:59:42 Organization
Name of person sending information
Name of person sending information
Organization1
Address1
Tel1
Email1
7 Update 2019/01/07 12:01:19 Recruitment status
Last follow-up date
8 Update 2019/01/07 13:13:32 Key exclusion criteria
Key exclusion criteria
9 Update 2019/01/11 15:28:37 Institutions
10 Update 2019/07/29 09:39:09 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Email1
Organization
Organization
Address
Address
Tel
Email
11 Update 2019/07/29 09:40:53 Date of IRB
12 Update 2020/07/07 15:55:56 Last follow-up date
13 Update 2020/07/07 16:41:59 Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
14 Update 2021/07/10 10:07:24 Recruitment status
15 Update 2023/01/10 09:20:04 Recruitment status
16 Update 2023/01/10 09:20:42 Publication of results
Number of participants that the trial has enrolled